Marijuana has documented benefits for a handful of specific medical conditions, with the strongest evidence supporting its use for certain types of epilepsy, nerve pain, muscle spasticity in multiple sclerosis, and chemotherapy-related nausea. Beyond those, the evidence gets thinner. Many conditions where people report relief from cannabis lack the rigorous clinical data to match, and a few popular claims turn out to be more complicated than they seem.
Epilepsy: The Strongest Case
Epilepsy is the one condition where a cannabis-derived medication has earned full FDA approval. Epidiolex, a purified form of CBD, is licensed for Dravet syndrome and Lennox-Gastaut syndrome, two severe childhood epilepsy disorders that often resist standard treatments. In clinical trials, children with Dravet syndrome who took CBD saw a 22.8 percentage-point greater reduction in monthly convulsive seizures compared to placebo. For Lennox-Gastaut syndrome, the drop seizure frequency fell by roughly 19 to 22 percent more than placebo, depending on the dose.
These numbers may sound modest, but for children experiencing dozens or hundreds of seizures per month, any meaningful reduction changes daily life. Epidiolex remains the only CBD drug product the FDA has approved, and no other cannabis-derived medication has cleared that bar for any condition.
Chronic Nerve Pain
Neuropathic pain, the burning, shooting type caused by nerve damage, is one of the better-studied targets for cannabis. A meta-analysis pooling results from multiple trials found that THC reduced pain intensity by about 8.7 points on a 0-to-100 scale compared to placebo, and a THC/CBD combination reduced it by about 6.6 points. Patients using THC were 1.85 times more likely to achieve at least a 30 percent reduction in pain.
The types of nerve pain studied include diabetic neuropathy, HIV-associated neuropathy, pain from spinal cord injuries, complex regional pain syndrome, and nerve pain tied to multiple sclerosis. Cannabis appears to work best as a complement to other pain treatments rather than a standalone solution, and it tends to help more with nerve-based pain than with inflammatory or musculoskeletal pain like arthritis or back strain.
Muscle Spasticity in Multiple Sclerosis
People with MS often experience painful muscle stiffness and spasms that interfere with movement and sleep. Cannabis-based treatments, particularly a prescription mouth spray containing both THC and CBD (sold as Sativex in many countries), have shown meaningful improvement in spasticity scores on standardized scales. Long-term use appears to produce larger effects than short-term use, suggesting the benefits may build over weeks of consistent treatment.
This is one of the few areas where medical marijuana has gained regulatory acceptance outside the United States. Several countries approve THC/CBD spray specifically for MS spasticity when patients haven’t responded well to other medications.
Chemotherapy-Induced Nausea
Cannabis has been used for chemotherapy nausea since the 1980s, and synthetic THC (dronabinol and nabilone) has long been available by prescription for this purpose. In pooled analyses, cannabinoids were 2.65 times more effective than placebo at controlling nausea and vomiting from chemotherapy. However, when compared head-to-head with standard anti-nausea medications, cannabinoids performed about the same, not better. Modern anti-nausea drug combinations have also improved significantly since the early studies were conducted, which means cannabis-based options now typically serve as a backup for patients who don’t respond to first-line treatments.
Appetite and Wasting Syndrome
Dronabinol, the synthetic THC pill, carries an FDA-approved indication for appetite loss associated with AIDS-related wasting. The weight gain results, however, are underwhelming. Across studies, patients on dronabinol gained between nothing and about 3.2 kilograms, and in at least one trial they actually lost 2 kilograms. Other appetite-stimulating drugs produced larger and more consistent weight gains in the same population. Still, dronabinol is generally well tolerated, and for patients who can’t use or don’t respond to alternatives, it provides a modest appetite boost.
Cancer patients experiencing appetite loss and weight loss also sometimes use cannabis for similar reasons, though the formal evidence base here is smaller and largely observational.
PTSD
Post-traumatic stress disorder is one of the most common reasons people seek medical marijuana cards in states that allow it. The existing research is encouraging but limited. In one study of 104 patients, PTSD symptom scores dropped from an average of 54.7 to 38.8 after treatment with a synthetic cannabinoid, a statistically significant improvement. A survey-based study found that 77 percent of patients reported reduced PTSD symptoms with cannabis use. A small CBD-only study showed that 10 out of 11 participants had meaningful symptom reduction at four weeks.
The caveat is that these studies are small, most lack strong controls, and a small but consistent subset of patients in each study experienced worsening symptoms. Cannabis may help some people with PTSD manage hyperarousal, nightmares, and anxiety, but it doesn’t work uniformly, and the quality of evidence is still low compared to established PTSD therapies.
Crohn’s Disease and Inflammatory Bowel Disease
Many people with Crohn’s disease report that cannabis eases abdominal pain, diarrhea, and poor appetite. The clinical trial data, though, is frustratingly inconclusive. In one small study of 21 patients, 91 percent of those smoking cannabis with THC achieved a clinical response (a meaningful drop in disease activity scores) compared to 40 percent on placebo. But when researchers looked specifically at full remission, the difference wasn’t statistically significant. A CBD-only oil showed no benefit over placebo for remission.
A third study using oil with both CBD and THC found notably lower disease activity scores after eight weeks (118.6 versus 212.6 for placebo), but didn’t report remission rates. The bottom line from a Cochrane review: cannabis may improve how Crohn’s disease feels day to day, particularly pain and appetite, but there’s no firm evidence it reduces the underlying intestinal inflammation or induces lasting remission.
Glaucoma: A Common Misconception
Glaucoma is one of the oldest associations with medical marijuana, dating back to research in the 1970s. Cannabis does lower eye pressure, but the effect lasts only 3 to 4 hours before pressure returns to baseline. Since glaucoma requires 24-hour pressure control, maintaining a therapeutic effect would require smoking 8 to 10 times per day, every day. That translates to roughly 2,920 to 3,650 uses per year. Modern glaucoma eye drops, by contrast, work with once or twice-daily dosing and don’t carry the cognitive side effects. No major ophthalmology organization recommends cannabis for glaucoma.
Sleep: More Complicated Than Expected
Many people use cannabis to fall asleep faster, and the subjective experience often confirms it works. But the objective sleep data tells a more nuanced story. In a controlled trial measuring brain activity during sleep, a THC/CBD combination actually decreased total sleep time by about 24.5 minutes compared to placebo. It also cut REM sleep by nearly 34 minutes and delayed the onset of REM sleep by over an hour.
REM sleep is the stage associated with dreaming, memory consolidation, and emotional processing. Suppressing it night after night may have consequences that offset the benefit of falling asleep more easily. For people using cannabis specifically to suppress nightmares (as in PTSD), REM reduction could be the desired effect. But for general insomnia, the tradeoff is less clearly favorable, and long-term sleep data on regular cannabis users remains limited.
What the Evidence Actually Supports
If you line up the conditions by strength of evidence, a clear hierarchy emerges. Severe childhood epilepsy has the most rigorous support, followed by neuropathic pain, MS spasticity, and chemotherapy nausea. PTSD, appetite loss, and Crohn’s disease have promising signals but weak study designs and small sample sizes. Glaucoma is largely a dead end for practical treatment. Sleep effects are real but potentially counterproductive depending on your goals.
State medical marijuana programs often approve cannabis for a much longer list of conditions than the clinical evidence firmly supports. That doesn’t mean it can’t help with those conditions. It means the question of whether it helps hasn’t been answered with the same rigor applied to conventional medications, partly because federal restrictions have historically made cannabis research difficult to conduct in the United States.